Compound Drugs Are Focus of Reports, Blogs, Laws - Risk ...
www.riskandinsurance.com/compound-drugs-focus-reports-blogs-laws/
Thursday, September 18, 2014
Compound Drugs Are Focus of Reports, Blogs, Laws - Risk ...
HIGH IMPORTANCE!! Must Read! Study Shows Inconsistent Dosages of Widely Used Eye Disease Drug FINDINGS ADD TO PUBLIC HEALTH DEBATE ABOUT PHARMACY COMPOUNDING
NEW YORK (September 18, 2014) — Custom-made versions of a widely prescribed, low-cost drug used to prevent a leading cause of blindness in the elderly vary widely in their dosages, Weill Cornell Medical College scientists found in analyses of the eye injections. Investigators saw no evidence of impurities or contamination but found that many of the samples, which were prepared by pharmacists through a process called compounding, contained less medication than doses of the drug obtained directly from the manufacturer. The research, published today in JAMA Ophthalmology, is likely to increase scrutiny of compounding pharmacies, which tailor-mix drugs for individual patients, and to question whether eye-care specialists should continue to prescribe the cancer drug Avastin for age-related macular degeneration (AMD).
continue to read here
continue to read here
New Executive Actions to Combat Antibiotic Resistance and Protect Public Health; FDA’s Take on the Executive Order and National Strategy to Combat Antibiotic-Resistant Bacteria
New Executive Actions to Combat Antibiotic Resistance and Protect Public Health –http://www.whitehouse.gov/
FDA’s Take on the Executive Order and National Strategy to Combat Antibiotic-Resistant Bacteria –http://blogs.fda.gov/fdavoice/
Second Question of the Day September 18, 2014 What is there a need to keep reannouncing or relaunching partnerships and advocacy group for compounding? How many non-compounding pharmacists are supporting and actively advocating to the extend compounding pharmacists want them to do so? How many consumers and healh care providers are now much more knowledgeable and questioning of compounding medications and the need for them?
IACP Launches Partnership for Personalized Prescriptions
https://finance.yahoo.com/news/iacp-launches-partnership-personalized-prescriptions-190100781.html
Medisca offering Essential of Non-Sterile Compounding
Essentials of Non-Sterile Compounding
Kenneth R. Speidel, Medisca Network Inc.
Tuesday, October 7, 2014 (Tentative)
1:00 – 2:00 p.m. CST (2:00 ET / 11:00 PT / 12:00 MT)
1:00 – 2:00 p.m. CST (2:00 ET / 11:00 PT / 12:00 MT)
IACP Technician or Student Pharmacist Members – $25
IACP Pharmacist Members – $45
Non-members – $70
IACP Pharmacist Members – $45
Non-members – $70
Registration will open in May!
The practice of compounding pharmacy has undergone a significant evolution in requirements and practices in just the past year, and predictions suggest change will continue for some time to come. It is imperative that we evolve our historically reactive behaviors to a more prospective behavior that will anticipate change far before a response is necessary. This one hour webinar will provide specific considerations that non-sterile compounding pharmacy personnel can utilize to protect their businesses from a business, operational or even a regulatory event.
At the conclusion of this program, the pharmacist and technician attendee will be able to:
- Outline business development and marketing concepts that lead to a successful practice and a competitive advantage.
- Identify dosage form stability and patient-specific suitability of compounded preparations that will provide a more systematic approach to individualization.
- Recognize the reasons to consider third party accreditation for your non-sterile pharmacy.
- Identify non-sterile compounding-related United States Pharmacopeia (USP) guidelines to employ in your compounding operations.
- Identify common problematic areas in non-sterile compounding pharmacy operations to add simple monitoring and reporting processes to the organizational Quality Management Program (QMP).
CRITICAL READ for CONSUMERS and HEALTH CARE PROVIDERS!! Compounded pain creams and adverse effects
Some compounding pharmacies are preparing compounded pain creams and ointments that contain a combination of multiple potent medications. Many include drugs that can cause central nervous system depression or cardiac effects such as ketamine, baclofen, cyclobenzaprine, lidocaine, tricyclic antidepressants, gabapentin, clonidine, and nifedipine. Most of these drugs have not been US Food and Drug Administration (FDA)-approved for topical use (although off-label use of medications is routine). Some compounding pharmacies are filling prescriptions for these pain creams for specific patients. Their use is growing, prompting some pharmacies to employ a sales force, initiate elaborate marketing campaigns, and provide template prescriptions to make prescribing of these creams easier. Prospective patients are even receiving unsolicited calls at home, with a promise that the cream can be prescribed after an arranged telephone consultation with a physician.
Read more at http://www.philly.com/philly/blogs/healthcare/Compounded-pain-creams-and-adverse-effects.html#LZMBIkop3JY8zOjL.99
Read more at http://www.philly.com/philly/blogs/healthcare/Compounded-pain-creams-and-adverse-effects.html#LZMBIkop3JY8zOjL.99
Subscribe to:
Posts (Atom)